RECRUITING

Psilocybin Therapy for Depression in Parkinson's Disease

Talk to us

Conditions

Parkinson DiseaseDepressionPsilocybinPsilocybin therapyMovement disorder

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this study is to understand whether people with Parkinson's Disease and depression have improvement in their symptoms after psilocybin therapy.

Official Title

The Efficacy of Psilocybin Therapy for Depression in Parkinson's Disease

Quick Facts

Study Start:2024-08-19
Study Completion:2028-06
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06455293

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:40 Years to 80 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Age 40 to 80
  2. * Comfortable speaking and writing in English
  3. * Have neurologist-diagnosed idiopathic Parkinson's disease (PD), Hoehn and Yahr stages 1 to 3 during an "on" phase (time when medication/DBS for parkinsonian motor feature, including bradykinesia and rigidity is in effect)
  4. * Currently experiencing depressive symptoms
  5. * Able to attend all in-person visits at UCSF as well as virtual visits
  6. * Have a primary care provider, neurologist, or psychiatrist who is actively managing or coordinating
  1. * Psychotic symptoms involving loss of insight
  2. * Significant cognitive impairment
  3. * Regular use of medications that may have problematic interactions with psilocybin
  4. * A health condition that makes this study unsafe or unfeasible, determined by study physicians

Contacts and Locations

Study Contact

Brigette Sosa
CONTACT
(415) 935-3489
pdp2@ucsf.edu
Ellen Bradley, MD
CONTACT
ellen.bradley@ucsf.edu

Principal Investigator

Joshua Woolley, MD,PhD
PRINCIPAL_INVESTIGATOR
University of California, San Francisco
Ellen Bradley, MD
STUDY_DIRECTOR
University of California, San Francisco

Study Locations (Sites)

University of California, San Francisco
San Francisco, California, 94143
United States

Collaborators and Investigators

Sponsor: Joshua Woolley, MD, PhD

  • Joshua Woolley, MD,PhD, PRINCIPAL_INVESTIGATOR, University of California, San Francisco
  • Ellen Bradley, MD, STUDY_DIRECTOR, University of California, San Francisco

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-08-19
Study Completion Date2028-06

Study Record Updates

Study Start Date2024-08-19
Study Completion Date2028-06

Terms related to this study

Keywords Provided by Researchers

  • Parkinson Disease
  • Depression
  • Psilocybin
  • Psilocybin therapy
  • Movement disorder

Additional Relevant MeSH Terms

  • Parkinson Disease
  • Depression